Alexandra S. Vasilyeva

Alexandra S. Vasilyeva

Auto-generated profile, based on publicly available information

Alexandra S. Vasilyeva

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2025 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
AMA. D. Molchanov
A. D. Molchanov
AVA. S. Vasilyeva
A. S. Vasilyeva
KSK. V. Smirnova
K. V. Smirnova
MNMarina V. Nemtsova
Marina V. Nemtsova
Epstein–Barr virus (EBV) is widespread among the human population and underlies development of numerous malignant neoplasms. The mechanism of EBV-associated carcinogenesis is based on the ability of viral proteins and microRNAs to cause genetic and epigenetic changes which can directly or indirectly stimulate cell growth, inhibit apoptosis, and protect tumor cells from the effects of their microenvironment and the host’s immune response. EBV can lead to development of such malignant neoplasms as Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal, gastric cancer, etc. The review discusses molecular mechanisms of EBV-associated carcinogenesis promoting the virus’s survival in the host’s cells, and regulating oncoproteins.The results of more than 500 studies from the PubMed, Google Scholar, ResearchGate, Web of Science, RSCI (Russian Science Citation Index) and CyberLeninka databases performed primarily in the last 10 years were analyzed. Literature analysis has shown that EBV has a wide variety of mechanisms to avoid immune surveillance which ensures its lifelong persistence in the human body. Expression of latent proteins (in particular, EBNA1, LMP1, and LMP2A) which modulate the host’s signaling pathways, suppress apoptosis, and alter the immune response, plays the key role in its survival. Additionally, it was established that the type of latency maintained in the infected cells affects the probability of malignant transformation. For example, type II latency is characteristic of the majority of epithelial tumors, while type III is associated with lymphomas. Transition from latent to lytic phase is accompanied by expression of proteins promoting carcinogenesis. In the literature, special attention is paid to the roles of LMP1 and LMP2A oncoproteins which activate PI3K/AKT and JAK/STAT pathways disturbing regulation of cell proliferation and apoptosis. EBV-induced tumors are often characterized by epigenetic changes supporting persistence of the virus and tumor cell growth.Therefore, EBV is capable of extorting multifactorial effects on the host cell which makes it an important subject of cancer virology. This confirms the necessity of further studies for refinement of molecular mechanisms of carcinogenesis and development of targeted therapeutic approaches to treatment of EBV-associated tumors.

28 February 2026 in Problems of Virology
Verified
Journal Article
Open access
PDF file
AVAlexandra S. Vasilyeva
Alexandra S. Vasilyeva
AMAlina A. Margusheva
Alina A. Margusheva
AMArtem D. Molchanov
Artem D. Molchanov
ARArtem Rtishchev
Artem Rtishchev
BCBogdan Cherepovich
Bogdan Cherepovich
ВСВасильева Александра Сергеевна
Васильева Александра Сергеевна
Introduction. Epstein–Barr virus (EBV) is a widespread gamma-herpesvirus associated with a number of malignancies, including nasopharyngeal carcinoma and gastric cancer (GC/EBV+). The primary oncogenic protein of EBV is latent membrane protein 1 (LMP1). Genetic variability of the LMP1 protein affects its oncogenic activity and clinical manifestations. Objective. To investigate the optimal threshold value for EBV viral load, determine the correlation between high viral load and the detection of the LMP1 gene in the blood of patients with GC/EBV+, and to identify mutations in the C-terminal domains of the LMP1 gene that may affect protein function. Materials and methods. Total DNA was extracted from 227 blood samples of GC patients. The LMP1 gene was amplified using nested PCR. EBV DNA viral load in blood samples was analyzed by qPCR, followed by receiver operating characteristic (ROC) analysis and interquartile range (IQR) assessment. A selection criterion for positive DNA samples (EBV+) was established based on the mean viral load and ROC threshold. Results. ROC curve analysis and descriptive statistics identified 23 EBV-positive (EBV+) DNA samples, with the following results: AUC (area under the curve) = 0.83, optimal threshold 526.92 copies/reaction, sensitivity 0.69, specificity 0.87, and mean viral load: 513.5 copies/reaction. A statistically significant association was found between detection of the LMP1 gene in the blood and viral load level (χ2 test p = 0.018; Mann–Whitney U test p 0.0001). Additionally, synonymous and nonsynonymous mutations were identified in regions of LMP1 gene coding the C-terminal activating domains (CTAR1 and CTAR2). Conclusion. The findings highlight the heterogeneous molecular nature of EBV-associated gastric cancer, including genetic mutations in the LMP1 gene.